Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04378426 · ClinicalTrials.gov registry record · Phase 2
Nitrous Oxide for PTSD
A Phase 2 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04378426: Clinical Trial Phase 2 study, sponsored by VA Office of Research and Development.
NCT04378426 is a Phase 2 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04378426, a Phase 2 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Post-traumatic stress disorder (PTSD) seriously disrupts the lives of many Veterans. Current first-line treatments, serotonin reuptake inhibitors or prolonged exposure therapy, take weeks to months to bring meaningful improvement, leaving Veterans experiencing prolonged suffering. A promising new treatment approach for rapidly reducing PTSD symptoms is nitrous oxide, an inhalation anesthetic and putative glutamate modulator that diminishes depression symptoms within 1 day and has limited side effects. If shown to be similarly effective in PTSD, nitrous oxide may add dramatically to the treatment armamentarium by bringing rapid symptom decrease before longer-term therapies take hold. The proposed projects test the efficacy of nitrous oxide in relieving Veteran's PTSD symptoms and, in parallel, explore how nitrous oxide may modify cognitive and pain outcomes.
Interventions
- DRUG Midazolam
- DRUG Saline
- DRUG Oxygen
- DRUG Nitrous Oxide
- DRUG Nitrogen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-10-07 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04378426
The ClinicalTrials.gov registry entry for NCT04378426 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Midazolam is the first listed.
NCT04378426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04378426 about?
NCT04378426 is a clinical study titled "Nitrous Oxide for PTSD". Post-traumatic stress disorder (PTSD) seriously disrupts the lives of many Veterans. Current first-line treatments, serotonin reuptake inhibitors or prolonged exposure therapy, take weeks to months to bring meaningful improvement, leaving Veterans experiencing prolonged suffering. A promising new tr...
What is the current status of trial NCT04378426?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2021-10-07. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT04378426?
The interventions under investigation include: Midazolam (DRUG), Saline (DRUG), Oxygen (DRUG), Nitrous Oxide (DRUG), Nitrogen (DRUG).
Who is sponsoring clinical trial NCT04378426?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.